Skip to main content
Skip to content
Case File
efta-01461626DOJ Data Set 10Other

EFTA01461626

Date
Unknown
Source
DOJ Data Set 10
Reference
efta-01461626
Pages
1
Persons
0
Integrity

Summary

Ask AI About This Document

0Share
PostReddit

Extracted Text (OCR)

EFTA Disclosure
Text extracted via OCR from the original document. May contain errors from the scanning process.
As of 5/8/14 2:10 pm Description Trade Date Quantity Current Price Unit Cost Market Value Current Total Cost Unrealized G/L SANGAMO BIOSCIENCES 5/28/2013 50,000.00 $ 12.17 $ 8.44 $ 608,500.00 422,214.00 186,286.00 BIOGEN 2/14/2012 2,095.00 $ 285.28 $ 119.55 $ 597,661.60 250,454.95 $ 347,206.65 FOUNDATION MEDICINE 1/13/2014 25,000.00 $ 24.13 $ 27.51 $ 603,250.00 687,663.50 S (84,413.50) GILEAD SCIENCES INC Multiple 8,100.00 $ 79.36 $ 79.41 $ 642,816.00 643,204.00 $ (388.00) Total Biotech $ 2,452,227.60 $ 2,003,536.45 $ 448,691.15 ARIAD PHARMACEUTICALS Multiple 16,535.00 $ 6.76 $ 17.60 $ 111,776.60 290,997.40 $ (179,220.80) PX_LAST CONFIDENTIAL - PURSUANT TO FED. R. CRIM. P. 6(e) CONFIDENTIAL DB-SDNY-0 123778 SDNY_GM_00269962 EFTA01461626

Forum Discussions

This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.

Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.